An interesting discussion on the past, present and future of ODACs, through the perspective of participating oncologists (external and from the FDA Oncology)

youtube.com/watch?v=MNZhNk…

In the spirit of CRC awareness month, a reminder of the heartbreaking but powerful memoir written by Julie Yip Williams Fight Colorectal Cancer

goodreads.com/en/book/show/3…

What a powerfully resonant piece on being a patient, one with cancer, before becoming a physician JAMA Network Open

jamanetwork.com/journals/jama/…

A unique discussion about legacy and leadership, through the lens of Pat Riley

youtu.be/wGk41P3-dqc?si…

Author and Physician Abraham Verghese on Family, Medicine, and Writing “...
youtu.be/EIqGQhRI0d4?si… via YouTube

A fascinating discussion, based upon the story of BTK inhibitors, featured in Nathan Vardi's book For Blood and Money FDA Oncology

youtube.com/watch?v=8L9CYR…

Join us this Friday as we host the 15th Annual Sandler Lecture in Nuclear Medicine and Molecular Imaging, featuring Satya (Nanu) Das of AstraZeneca and his lecture 'From Investigator to Industry - A Perspective on Oncology Drug Development'

Register now: bit.ly/3QPqwgo

Always a treat to be invited back to Vanderbilt University Medical Center and honored to give the Sandler Lecture Vanderbilt Radiology about radionuclide drug development through the lens of both investigator & industry

vumc.org/radiology/radi…

Honored to share a small reflection on drug development from my prior life as a clinical investigator to current perspective JAMA Oncology AstraZeneca

jamanetwork.com/journals/jamao…

This article reviews major #carcinoid heart disease guidance papers and provides perspectives on how to implement the recommendations into clinical practice. Satya (Nanu) Das doi.org/10.1093/oncolo…

Very exciting news for the NET community, to see the success of cabozantinib in EP-NETs and PNETs. Congrats Dr. Chan and colleagues CarcinoidCancer CCF NET Research Foundation NCAN Dana-Farber

onclive.com/view/cabozanti…

Congrats to superstar Shannon Stockton MD for presenting our gastric/GEJ trial of irinotecan/berzosertib, 5 years in the making. This speaks to the ongoing story of mentors (the best, in Dr. jordan berlin ) and mentees. Vanderbilt Hem / Onc Vanderbilt-Ingram Cancer Center NCI CTEP Clinical Research

Thrilled to share our review on the multidisciplinary mgmt of carcinoid heart disease, always a treat to collab w/ Shannon Stockton MD and others
The Oncologist CarcinoidCancer CCF NET Research Foundation

Carcinoid Heart Disease Management: A Multi-Disciplinary Collaboration academic.oup.com/oncolo/article…

Meta-analysis of 20 years’ worth of phase 2/3 clinical trials demonstrates efficacy + safety of targeted anti-VEGF therapies for neuroendocrine tumors, per Oncology Advance report. Satya (Nanu) Das @jordanberlin5@VUMCHemOnc Vanderbilt-Ingram Cancer Center
news.vumc.org/2023/02/16/tar…

Here is the link to the full article:

authors.elsevier.com/a/1gX3a3QE--VJ…

Happy to share our meta-analysis assessing efficacy and toxicity of anti-VEGF TKIs in NETs. Not possible with the contributions of some amazing colleagues. Oncology Advance NANETS Vanderbilt-Ingram Cancer Center Vanderbilt Hem / Onc NET Research Foundation

ejcancer.com/article/S0959-…

A testament to the odyssey of many NET patients prior to diagnosis. Honored to have been involved in this piece Vanderbilt-Ingram Cancer Center Vanderbilt Hem / Onc

NET in the news! Kudos to the PCP who listened and pursued a correct diagnosis and to Washington Post for describing NET accurately! LACNETS NET Cancer Day Healing NET CarcinoidCancer CCF NANETS NET Research Foundation Satya (Nanu) Das

A well written piece on how we as field can evolve phase 1 #oncology trial design and conduct to meet the demands of the changing nature of our therapeutics Vanderbilt-Ingram Cancer Center Annals of Oncology

annalsofoncology.org/article/S0923-…

As I have said before, I learn from everybody who calls themselves my mentee. The hardest part is letting them leave the nest but we know Satya (Nanu) Das will soar in his new role. So proud of everything you have accomplished here and in the future. Not goodbye. Just so long.